RecruitingPhase 3NCT07816562

Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)

Ovulation Trigger Strategies in Women With Low Ovarian Reserve Undergoing Fresh In Vitro Fertilization Cycles: A Prospective Randomized Controlled Trial (TRIGGERBEST)


Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Enrollment

126 participants

Start Date

Sep 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare different ovulation triggering strategies in women with low ovarian reserve undergoing fresh in vitro fertilization (IVF) cycles. Ovulation triggering is a key step in IVF treatment, as it determines final oocyte maturation prior to oocyte retrieval. Participants are randomly assigned to one of three ovulation trigger approaches: human chorionic gonadotropin (hCG) alone, follitropin delta combined with hCG, or dual trigger using a gonadotropin-releasing hormone (GnRH) agonist plus hCG. The primary objective is to evaluate wether adding follitropin delta at the time of triggering increases the number of matura oocytes obtained, without adversely affecting implantation rates. Pregnancy otucomes following fresh embryo transfer will also be assessed. The results of this study may help optimize ovulation triggering strategies in women with low ovarian reserve undergoing IVF treatment.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 42 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Follitropin delta, a drug called Human chorionic gonadotropin (hCG), and others for people with low ovarian reserve and poor ovarian response. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHuman chorionic gonadotropin (hCG)

Human chorionic gonadotropin (hCG) administered for final oocyte maturation and ovulation triggering.

DRUGFollitropin delta

Follitropin delta administered as part of the ovulation-triggering regimen for final oocyte maturation. (hCG).

DRUGTriptorelin

Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, administered as part of the ovulation-triggering regimen for final oocyte maturation.


Locations(1)

Hospital Clínico Universitario de Valencia

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07816562


Related Trials